Tara Gregory, MD, Colorado Blood Cancer Institute, Denver, CO, discusses the results of a Phase I/II trial (NCT03288493) of P-BCMA-101 CAR-T cell therapy in relapsed/refractory multiple myeloma (MM). P-BCMA-101 is an autologous CAR-T cell therapy that targets BCMA, manufactured via a novel transposon-based system to increase efficacy and reduce toxicity. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
Phase I/II trial of P-BCMA-101 CAR-T cell therapy in R/R myeloma
Теги
Speaker: Tara GregoryInstitution: Colorado Blood Cancer InstituteEvent: VJVirtualEvent: ASH 2020Format: InterviewSubject: Multiple MyelomaMedicines: CAR-TMedicines: P-BCMA-101Medicines: RituximabMedicines: LenalidomideMedicines: AntibodiesField: CAR-T & Cellular TherapyField: Immuno-OncologyField: TreatmentField: Trial UpdatesimmunotherapyBCMAmonoclonal antibodiesCD20cytokine release syndromeCRSoverall response rateORRsafetyNCT03288493
